BioSpace News Archive

Shanghai Junshi Biosciences Co., Ltd. announced that the National Medical Products Administration of China has approved its supplemental New Drug Application for toripalimab in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic nasopharyngeal carcinoma.

Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at the Cytokine-Based Cancer Immunotherapies Summit occurring November 30th to December 2nd, 2021 in Boston, MA.

AB Science SA (Euronext - FR0010557264 - AB) today announced that the first patient has been dosed in the phase 2 trial evaluating the antiviral activity of masitinib in patients who have a confirmed diagnosis of COVID-19.

Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 400 employers and millions of members, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference.

AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, announced the appointment of Mr. Daniel Faga to the company’s Board of Directors.

Prothena Corporation plc (NASDAQ:PRTA), today announced that members of its senior management team will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Monday December 6, 2021 at 1:20 PM ET.

Amgen announced that it has been named to the Dow Jones Sustainability World Index for the eighth consecutive year, reflecting the company’s enduring commitment to environmental, social, and governance issues.

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on January 5, 2022 to all shareholders of record as of December 15, 2021.

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company reducing the cost and complexity of dialysis, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for a new sterilization method of the cartridge utilized in its Tablo® Hemodialysis System, enabling full production in North America.

Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), today announced the filing of its fiscal second-quarter results for the three-month period ending September 30, 2021.